| Trial ID: | L2174 |
| Source ID: | NCT06706791
|
| Associated Drug: |
Empagliflozin 10 Mg
|
| Title: |
Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Heart Failure
|
| Interventions: |
DRUG: Empagliflozin 10 MG
|
| Outcome Measures: |
Primary: improvement in Kansas city cardiomyopathy questionnaire scoring, Primary outcome measure will be the improvement in quality of life indicating by change in Kansas City cardiomyopathy questionnaire (KCCQ) scoring. higher value indicates better results., 18 months | Secondary: assessment of NT-pro-BNP levels., Secondary outcome measures will include the change in NT-pro-BNP levels.lower values indicates better results, 18 months
|
| Sponsor/Collaborators: |
Sponsor: Fazaia Ruth Pfau Medical College
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
156
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2025-04-01
|
| Completion Date: |
2026-12-01
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-21
|
| Locations: |
Fazaia Ruth Pfau Hospital, Karachi, Sindh, 75120, Pakistan
|
| URL: |
https://clinicaltrials.gov/show/NCT06706791
|
